Yet another ten stories on antiviral drug discovery (part D): Paradigms, paradoxes, and paraductions

Medicinal Research Reviews

Volumn 30, Issue 4, 2010, Pages 667-707

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Acyclic nucleoside phosphonates (ANPs); BPIP; CADA; Cidofovir; HIV; Papillomatosis; Prophylactic; T 705; TBZ; Tenofovir; Veterinary

Indexed keywords

1H,3H THIAZOLO[3,4 A]BENZIMIDAZOLE DERIVATIVE; 2 (2,3 DIFLUOROPHENYL) 5 [4 (TRIFLUOROMETHYL)BENZYL] 5H IMIDAZO[4,5 C]PYRIDINE; 2 (2,3 DIFLUOROPHENYL) 5 [[3 (4 CHLOROPHENYL) 5 ISOXAZOLYL]METHYL] 5H IMIDAZO[4,5 C]PYRIDINE; 5 BENZYL 2 PHENYL 5H IMIDAZO[4,5 C]PYRIDINE DERIVATIVE; 5 [(4 BROMOPHENYL)METHYL] 2 (2 FLUOROPHENYL) 5H IMIDAZO[4,5 C]PYRIDINE; 5 [(4 BROMOPHENYLMETHYL) 2 PHENYL 5H IMIDAZO[4,5 C]PYRIDINE]; 9 BENZYL 3 METHYLENE 1,5 DI 4 TOLUENESULFONYL 1,5,9 TRIAZACYCLODODECANE; AG 110; ANTIVIRUS AGENT; APLAVIROC; CIDOFOVIR; CYCLOSPORIN A DERIVATIVE; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; CYCLOTRIAZADISULFONAMIDE; ENFUVIRTIDE; FAVIPIRAVIR; GS 327073; N DIAZINYL N' [2 (2 PYRIDYL)ETHYL]THIOUREA; N PROPYL N [2 (2H 1,2,4 TRIAZINO[5,6 B]INDOL 3 YLTHIO)ETHYL] 1 PROPANAMINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE PHOSPHONATE; PLERIXAFOR; PYRAZINAMIDE; PYRIDAZINO[3,4 B][1,5] 1,5 BENZODIAZEPIN 5 ONE; RAPAMYCIN; RIBAVIRIN; RILPIVIRINE; ST 246; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; VP 32947; VETERINARY DRUG;

CONDYLOMA ACUMINATUM; DENGUE; DRUG RESEARCH; HEMORRHAGIC FEVER; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHARYNX CARCINOMA; LARYNX PAPILLOMATOSIS; MONKEYPOX; PAPILLOMATOSIS; POXVIRUS INFECTION; PROPHYLAXIS; RECURRENT RESPIRATORY PAPILLOMATOSIS; REVIEW; VERRUCA PLANTARIS; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; VIRUS DISEASES;

ANIMALS; ANTIVIRAL AGENTS; DRUG DISCOVERY; HUMANS; VETERINARY DRUGS; VIRUS DISEASES;

EID: 77953381888     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20173     Document Type: Review

References (292)

1. De Clercq E. The discovery of antiviral agents: Ten different compounds, ten different stories. Med Res Rev 2008;28:929-953.
2. De Clercq E. Antiviral drug discovery: Ten more compounds, and ten more stories (part B). Med Res Rev 2009;29:571-610.
3. De Clercq E. Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives. Med Res Rev 2009;29:611-645.
4. nd American Chemical Society National Meeting, Chicago, IL, 26-30 August 2001. Abstracts, No. 100.
5. Bell TW. Anti-viral triaza compounds. US Patent, 2 September 1997, 5,663,161.
6. Schols D, Zhang Y, Princen K, Hatse S, Samala MF, Dey K, Choi H-J, Ahn Y, Sodoma A, Snoeck R, Andrei G, De Clercq E, Bell TW, Schols D. CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 2002;302:342-353.
7. Schols D, Baba M, Pauwels R, Desmyter J, De Clerq E. Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor. Proc Natl Acad Sci USA 1999;86:3322-3326.
8. Zhang Y, Schols D, De Clercq E. Selective activity of various antiviral compounds against HHV-7 infection. Antiviral Res 1999;43:23-35. (Pubitemid 29361499)
9. Vermeire K, Bell TW, Choi H-J, Jin Q, Samala MF, Sodoma AJ, De Clercq E, Schols D. The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol Pharmacol 2003;63:203-210.
10. Vermeire K, Princen K, Hatse S, De Clercq E, Dey K, Bell TW, Schols D. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS 2004;18:2115-2125. (Pubitemid 39463676)
11. Vermeire K, Lisco A, Grivel J-C, Scarbrough E, Dey K, Duffy N, Margolis L, Bell TW, Schols D. Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity. Biochem Pharmacol 2007;74:566-578.
12. Bell TW, Anugu S, Bailey P, Catalano VJ, Dey K, Drw MGB, Duffy NH, Jin Q, Samala MF, Sodoma A, Welch WH, Schols D, Vermeire K. Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues. J Med Chem 2006;49:1291-1312. (Pubitemid 43271884)
13. Vermeire K, Schols D. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Expert Opin Investig Drugs 2005;14:1199-1212.
14. Vermeire K, Schols D. Specific CD4 down-modulating compounds with potent anti-HIV activity. J Leukoc Biol 2003;74:667-675.
15. Vermeire K, Schols D. Cyclotriazadisulfonamides: Promising new CD4-targeted anti-HIV drugs. J Antimicrob Chemother 2005;56:270-272.
16. Vermeire K, Schols D, Bell TW. Inhibitors of HIV infection via the cellular CD4 receptor. Curr Med Chem 2006;13:731-743.
17. Vermeire K, Van Laethem K, Vandamme A-M, Bell TW, De Clercq E, Schols D. Resistance profile of human immunodeficiency virus to CADA, a novel HIV inhibitor that targets the cellular CD4 receptor. Abstracts of the Eighteenth International Conference on Antiviral Research, Barcelona, Spain, 11-14 April 2005. Antiviral Res 2005;70:A43-A44, No. 34.
18. Vermeire K, Brouwers J, Van Herrewege Y, Le Grand R, Vanham G, Augustijns P, Bell TW, Schols D. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Curr HIV Res 2008;6:246-256. (Pubitemid 352024677)
19. Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominque JK, Klingebiel E, Gallo RC, Redfield RR. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: An approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA 2003;100:10411-10416. (Pubitemid 37071892)
20. Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR. Rapamycin reduces CCR5 density levels on CD4 T cells and this effect results in potentiation of enfuvirtide (T-20) against R5 HIV-1 in vitro. Antimicrob Agents Chemother 2007;51:2489-2496.
21. Heredia A, Latinovic O, Gallo RC, Melikyan GB, Reitz M, Le N, Redfield R. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci USA 2008;105:20476-20481.
22. Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR. Rapamycin enhances aplaviroc anti-HIV activity: Implications for the clinical development of novel CCR5 antagonists. Antiviral Res 2009;83:86-89.
23. Easmon J, Heinisch G, Pürstinger G, Langer T, Sterreicher JK, Grunicke HH, Hofmann J. Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: Synthesis and antiproliferative activity. J Med Chem 1997;40:4420-4425. (Pubitemid 28042322)
24. Hall IH, Peaty NJ, Henry JR, Easmon J, Heinisch G, Pürstinger G. Investigations on the mechanism of action of the novel antitumor agents 2-benzothiazolyl, 2-benzoxazolyl, and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine. Arch Pharm Pharm Med Chem 1999;332:115-123. (Pubitemid 29190034)
25. Easmon J, Pürstinger G, Roth T, Fiebig HH, Jenny M, Jaeger W, Heinisch G, Hofmann J. 2-Benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: A novel class of antitumor agents. Int J Cancer 2001;94:89-96. (Pubitemid 32801757)
26. Easmon J, Pürstinger J, Heinisch G, Roth T, Fiebig HH, Holzer W, Jäger W, Jenny M, Hofmann J. Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II) complexes of (4)N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines. J Med Chem 2001;44:2164-2171.
27. Easmon J, Pürstinger G, Thies K-S, Heinisch G, Hofmann J. Synthesis, structure-activity relationships, and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroaromatics. J Med Chem 2006;49:6343-6350.
28. Heinisch G, Huber E, Leitner C, Matuszczak B, Maurer A, Pachler S, Prillinger U. Pyridazino[3,4-b][1,5]benzodiazepin-5-ones: Synthesis and biological evaluation. Antivir Chem Chemother 1997;8:371-379.
29. Heinisch G, Matuszczak B, Pachler S, Rakowitz D. The inhibitory activity of diazinyl-substituted thiourea derivatives on human immunodeficiency virus type 1 reverse transcriptase. Antivir Chem Chemother 1997;8:443-446. (Pubitemid 27376172)
30. Buckwold VE, Beer BE, Donis RO. Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents. Antiviral Res 2003;60:1-15. (Pubitemid 37153391)
31. Pürstinger G, Paeshuyse J, Herdewijn P, Rozenski J, De Clercq E, Neyts J. Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: A new class of pestivirus inhibitors. Bioorg Med Chem Lett 2006;16:5345-5349.
32. Paeshuyse J, Leyssen P, Mabery E, Boddeker N, Vrancken R, Froeyen M, Ansari IH, Dutartre H, Rozenski J, Gil LHVG, Letellier C, Lanford R, Canard B, Koenen F, Kerkhofs P, Donis RO, Herdewijn P, Watson J, De Clercq E, Pürstinger G, Neyts J. A novel, highly selective inhibitor of pestivirus replication that targets the viral RNA-dependent RNA polymerase. J Virol 2006;80:149-160.
33. Baginski SG, Pevear DC, Seipel M, Sun SC, Benetatos CA, Chunduru SK, Rice CM, Collett MS. Mechanism of action of a pestivirus antiviral compound. Proc Natl Acad Sci USA 2000;97:7981-7986.
34. Paeshuyse J, Chezal J-M, Froeyen M, Leyssen P, Dutartre H, Vrancken R, Canard B, Letellier C, Li T, Mittendorfer H, Koenen F, Kerkhofs P, De Clercq E, Herdewijn P, Pürstinger G, Gueiffier A, Chavignon O, Teulade J-C, Neyts J. The imidazopyrrolopyridine analogue AG110 is a novel, highly selective inhibitor of pestiviruses that targets the viral RNA-dependent RNA polymerase at a hot spot for inhibition of viral replication. J Virol 2007;81:11046-11053.
35. Paeshuyse J, Letellier C, Froeyen M, Dutartre H, Vrancken R, Canard B, De Clercq E, Gueiffier A, Teulade J-C, Herdewijn P, Puerstinger G, Koenen F, Kerkhofs P, Baraldi PG, Neyts J. A pyrazolotriazolopyrimidinamine inhibitor of bovine viral diarrhea virus replication that targets the viral RNA-dependent RNA polymerase. Antiviral Res 2009;82:141-147.
36. Vrancken R, Paeshuyse J, Haegeman A, Pürstinger G, Froeyen M, Herdewijn P, Kerkhofs P, Neyts J, Koenen F. Imidazo[4,5-c]pyridines inhibit the in vitro replication of the classical swine fever virus and target the viral polymerase. Antiviral Res 2008;77:114-119.
37. Pürstinger G, Paeshuyse J, De Clercq E, Neyts J. Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: From anti-pestivirus to anti-hepatitis C virus activity. Bioorg Med Chem Lett 2007;17:390-393.
38. Pürstinger G, Paeshuyse J, De Clercq E, Neyts J. Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: From anti-pestivirus to anti-hepatitis C virus activity. Bioorg Med Chem Lett 2007;17:390-393.
39. Pürstinger G, Paeshuyse J, Heinrich S, Mohr J, Schraffl N, De Clercq E, Neyts J. Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: Further optimization of anti-hepatitis C virus activity. Bioorg Med Chem Lett 2007;17:5111-5114.
40. Vliegen I, Paeshuyse J, Lehman LS, Zhong W, Roofthooft S, Dutartre H, Selisko B, Canard B, Boddeker N, Bondy S, Oare D, De Clercq E, Lee WA, Pürstinger G, Neyts J. Substituted imidazopyridines as potent inhibitors of hepatitis C virus replication that target the viral polymerase. Abstracts of the 20th International Conference on Antiviral Research, Palm Springs, CA, USA, 29 April-3 May 2007. Antiviral Res 2007;74:A37, No. 26.
41. Vliegen I, Paeshuyse J, De Burghgraeve T, Lehman LS, Paulson M, Shih IH, Mabery E, Boddeker N, De Clercq E, Reiser H, Oare D, Lee WA, Zhong W, Bondy S, Pürstinger G, Neyts J. Substituted imidazopyridines as potent inhibitors of HCV replication. J Hepatol 2009;50:999-1009.
42. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007;6:1001-1018.
43. Paeshuyse J, Vliegen I, Coelmont L, Leyssen P, Tabarrini O, Herdewijn P, Mittendorfer H, Easmon J, Cecchetti V, Bartenschlager R, Pürstinger G, Neyts J. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob Agents Chemother 2008;52:3433-3437.
44. McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang W-R, Kang H, Symons J, Cammack N, Najera I. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob Agents Chemother 2008;52:1604-1612.
45. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PA, Hughes SH, Arnold E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol 1995;2:407-415.
46. Chimirri A, Grasso S, Monforte AM, Monforte P, Zappala M. Thiazobenzimidazoles as nonnucleoside HIV-1 RT inhibitors. Abstracts of the II Congresso Congiunto Italiano-Spagnolo di Chimica Farmaceutica/II Congreso Conjunto Italiano-Espanol de Quimica Terapeutica, Ferrara, Italy, 30 August-3 September 1995, ML20.
47. Roth T, Morningstar ML, Boyer PL, Hughes SH, Buckheit Jr RW, Michejda CJ. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles. J Med Chem 1997;40:4199-4207. (Pubitemid 28042301)
48. Chimirri A, Grasso S, Monforte AM, Monforte P, Zappalà M. Anti-HIV agents. I: Synthesis and in vitro anti-HIV evaluation of novel 1H,3H-thiazolo[3,4-a]benzimidazoles. Il Farmaco 1991;46:817-823.
49. Chimirri A, Grasso S, Monforte AM, Monforte P, Zappalà M. Anti-HIV agents II. Synthesis and in vitro anti-HIV activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles. Il Farmaco 1991;46:925-933.
50. Chimirri A, Grasso S, Monforte AM, Monforte P, Zappalà M. Anti-HIV agents. III. Synthesis and in vitro anti-HIV activity of novel 1H,3H-thiazolo[3,4-a]imidazo[4,5-b]pyridines. Il Farmaco 1994;49:345-348.
51. Chimirri A, Grasso S, Molica C, Monforte AM, Monforte P, Zappalà M, Scopelliti R. Anti-HIV agents. IV. Synthesis and in vitro anti-HIV activity of novel 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazoles. Il Farmaco 1996;51:279-282.
52. Chimirri A, Grasso S, Monforte AM, Monforte P, Rao A, Zappalà M, Bruno G, Nicolò F, Scopelliti R. Anti-HIV agents. V. Synthesis, structure and in vitro anti-HIV activity of novel 1H,3H-naphtho[2′,3′:4,5] imidazo[1,2-c]thiazoles. Il Farmaco 1997;52:673-677.
53. Chimirri A, Grasso S, Molica C, Monforte A-M, Monforte P, Zappalà M, Bruno G, Nicolò F, Witvrouw M, Jonckheere H, Balzarini J, De Clercq E. Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2′,6′-difluorophenyl)-1H,3H-thiazolo[3,4-a] benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antivir Chem Chemother 1997;8:363-370.
54. Chimirri A, Grasso S, Monforte AM, Monforte P, Rao A, Zappalà M, Bruno G, Nicolò F, Pannecouque C, Witvrouw M, De Clercq, E. Synthesis, structure and in vitro anti-human immunodeficiency virus activity of novel 3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles. Antivir Chem Chemother 1998;9:431-438
55. Chimirri A, Grasso S, Monforte P, Rao A, Zappalà M, Monforte AM, Pannecouque C, Witvrouw M, Balzarini J, De Clercq E. Synthesis and biological activity of novel 1H,3H-thiazolo[ 3,4-a]benzimidazoles: Non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antivir Chem Chemother 1999;10:211-217.
56. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance development. Med Res Rev 1996;16:125-157. (Pubitemid 26099986)
57. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998;38:153-179. (Pubitemid 29065480)
58. Chimirri A, Monforte P, Rao A, Zappalà M, Monforte AM, De Sarro G, Pannecouque C, Witvrouw M, Balzarini J, De Clercq E. Synthesis, biological activity, pharmacokinetic properties and molecular modelling studies of novel 1H,3H-oxazolo[3,4-a]benzimidazoles: Non-nucleoside HIV-1 reverse transcriptase inhibitors. Antivir Chem Chemother 2001;12:169-174.
59. Barreca ML, Chimirri A, De Luca L, Monforte A-M, Monforte P, Rao A, Zappalà M, Balzarini J, De Clercq E, Pannecouque C, Witvrouw M. Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg Med Chem Lett 2001;11:1793-1796.
60. Barreca ML, Balzarini J, Chimirri A, De Clercq E, De Luca L, Höltje HD, Höltje M, Monforte AM, Monforte P, Pannecouque C, Rao A, Zappalà M. Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. J Med Chem 2002;45:5410-5413.
61. Rao A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalà A. Synthesis and anti-hIV activity of 1-(2,6-difluorophenyl)-1H, 3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles. Il Farmaco 2002;57:819-823.
62. Rao A, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalà M. Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives. Il Farmaco 2002;57:747-751.
63. Rao A, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalà M. Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Il Farmaco 2003;58:115-120.
64. Barreca ML, Chimirri A, De Clercq E, De Luca L, Monforte A-M, Monforte P, Rao A, Zappalà M. Anti-HIV agents: Design and discovery of new potent RT inhibitors. Il Farmaco 2003;58:259-263.
65. Barreca ML, Rao A, De Luca L, Zappalà M, Monforte A-M, Maga G, Pannecouque C, Balzarini J, De Clercq E, Chimirri A, Monforte P. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J Med Chem 2005;48:3433-3437.
66. Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalà M. Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Il Farmaco 2004;59:33-39.
67. Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalà M. 2-(2,6-Dihalophenyl)-3-(pyrimidin- 2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antiviral Res 2004;63:79-84.
68. Barreca ML, Rao A, De Luca L, Iraci N, Monforte A-M, Maga G, De Clercq E, Pannecouque C, Balzarini J, Chimirri A. Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg Med Chem Lett 2007;17:1956-1960.
69. Monforte A-M, Rao A, Logoteta P, Ferro S, De Luca L, Barreca ML, Iraci N, Maga G, De Clercq E, Pannecouque C, Chimirri A. Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem 2008;16:7429-7435.
70. Das K, Bauman JD, Clark Jr AD, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci USA 2008;105:1466-1471. (Pubitemid 351346537)
71. Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of nonnucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 2005;88:209-231. (Pubitemid 39579659)
72. Morningstar ML, Roth T, Farnsworth DW, Smith MK, Watson K, Buckheit Jr RW, Das K, Zhang W, Arnold E, Julias JG, Hughes SH, Michejda CJ. Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. J Med Chem 2007;50:4003-4015.
73. De Palma AM, Heggermont W, Leyssen P, Pürstinger G, Wimmer E, De Clercq E, Rao A, Monforte AM, Chimirri A, Neyts J. Anti-enterovirus activity and structure-activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles. Biochem Biophys Res Commun 2007;353:628-632.
74. De Palma AM, Heggermont W, Lanke K, Coutard B, Bergmann M, Monforte AM, Canard B, De Clercq E, Chimirri A, Pürstinger G, Rohayem J, van Kuppeveld F, Neyts J. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol 2008;82:4720-4730.
75. Hayden F. Developing new antiviral agents for influenza treatment: What does the future hold? Clin Infect Dis 2009;48:S3-S13.
76. De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006;5:1015-1025. (Pubitemid 44835128)
77. Salomon R, Franks J, Govorkova EA, Ilyushina NA, Yen HL, Hulse-Post DJ, Humberd J, Trichet M, Rehg JE, Webby RJ, Webster RG, Hoffmann E. The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. J Exp Med 2006;203:689-697.
78. Kawaoka Y, Krauss S, Webster RG. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989;63:4603-4608.
79. Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN, Chen J. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 2003;100:2718-2723.
80. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004;101:8676-8681. (Pubitemid 38745830)
81. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA 2004;101:8682-8686.
82. Tuttle JV, Tisdale M, Krenitsky TA. Purine 20-deoxy-20-fluororibosides as antiinfluenza virus agents. J Med Chem 1993;36:119-125. (Pubitemid 23040152)
83. Tisdale M, Ellis M, Klumpp K, Court S, Ford M. Inhibition of influenza virus transcription by 2′-deoxy-2′-fluoroguanosine. Antimicrob Agents Chemother 1995;39:2454-2458.
84. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002;46:977-981.
85. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005;49:981-986.
86. Takahashi K, Furuta Y, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura H, Egawa H, Minami S, Shiraki K. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother 2003;14:235-241.
87. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong M-H, Morrey JD, Furuta Y. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007;51:845-851.
88. Tomassini JE, Davies ME, Hastings JC, Lingham R, Mojena M, Raghoobar SL, Singh SB, Tkacz JS, Goetz MA. A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob Agents Chemother 1996;40:1189-1193.
89. Tomassini J, Selnick H, Davies ME, Armstrong ME, Baldwin J, Bourgeois M, Hastings J, Hazuda D, Lewis J, McClements W. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 1994;38:2827-2837. (Pubitemid 24374443)
90. Hastings JC, Selnick H, Wolanski B, Tomassini JE. Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob Agents Chemother 1996;40:1304-1307.
91. Cianci C, Chung TDY, Meanwell N, Putz H, Hagen M, Colonno RJ, Krystal M. Identificatin of N-hydroxamic acid and N-hydroxyimide compounds that inhibit the influenza virus polymerase. Antivir Chem Chemother 1996;7:353-360. (Pubitemid 26381365)
92. Parkes KE, Ermert P, Fässler J, Ives J, Martin JA, Merrett JH, Obrecht D, Williams G, Klumpp K. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J Med Chem 2003;46:1153-1164. (Pubitemid 36428221)
93. Nakazawa M, Kadowaki SE, Watanabe I, Kadowaki Y, Takei M, Fukuda H. PA subunit of RNA polymerase as a promising target for anti-influenza virus agents. Antiviral Res 2008;78:194-201.
94. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-650. (Pubitemid 30070911)
95. Droeber K, Ehrhardt C, Poetter A, Ludwig S, Planz O. CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice. Antiviral Res 2007;76:1-10. (Pubitemid 47176688)
96. Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, Poetter A, Dreschers S, Schmolke M, Planz O, Ludwig S. A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral Res 2007;76:38-47.
97. Shimizu T, Hino A, Tsutsumi A, Park YK, Watanabe W, Kurokawa M. Anti-influenza virus activity of propolis in vitro and its efficacy against influenza infection in mice. Antivir Chem Chemother 2008;19:7-13.
98. Liu A-L, Liu B, Qin H-L, Lee SMY, Wang Y-T, Du G-H. Anti-influenza virus activities of flavonoids from the medicinal plant Elsholtzia rugulosa. Planta Med 2008;74:847-851. (Pubitemid 351991120)
99. Gowen BB, Wong M-H, Jung K-H, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007;51:3168-3176.
100. Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, Christensen AJ, Furuta Y. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 2008;80:377-379.
101. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 2009;53:202-209.
102. Gowen BB, Smee DF, Wong MH, Hall JO, Jung KH, Bailey KW, Stevens JR, Furuta Y, Morrey JD. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS ONE 2008;3:e3725.
103. Julander JG, Furuta Y, Shafer K, Sidwell RW. Activity of T-1106 in a hamster model of yellow fever virus infection. Antimicrob Agents Chemother 2007;51:1962-1966. (Pubitemid 46903080)
104. Heifets LB, Lindholm-Levy PJ. Is pyrazinamide bactericidal against Mycobacterium tuberculosis? Am Rev Respir Dis 1990;141:250-252.
105. Zhang H, Deng J-Y, Bi L-J, Zhou Y-F, Zhang Z-P, Zhang C-G, Zhang Y, Zhang X-E. Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazina- midase. FEBS J 2008;275:753-762.
106. Salfinger M, Crowle AJ, Reller IB. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. J Infect Dis 1990;162:201-207. (Pubitemid 20223970)
107. Zimhony O, Cox JS, Welch JT, Vilchè ze C, Jacobs Jr WR. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 2000;6:1043-1047.
108. Zimhony O, Vilchè ze C, Arai M, Welch JT, Jacobs Jr WR. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. Antimicrob Agents Chemother 2007;51:752-754.
109. Ngo SC, Zimhony O, Chung WJ, Sayahi H, Jacobs Jr WR, Welch JT. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob Agents Chemother 2007;51:2430-2435. (Pubitemid 47047321)
110. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996;2:662-667. (Pubitemid 26191953)
111. Juré en P, Werngren J, Toro J-C, Hoffner S. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008;52:1852-1854.
112. Cynamon MH, Speirs RJ, Welch JT. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob Agents Chemother 1998;42:462-463.
113. Andrei G, De Clercq E. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res 1993;22:45-75. (Pubitemid 23256719)
114. Gould EA, Solomon T. Pathogenic flaviviruses. Lancet 2008;371:500-509.
115. Ghosh D, Basu A. Present perspectives on flaviviral chemotherapy. Drug Discov Today 2008;13:619-624.
116. Gibbons RV, Vaughn DW. Dengue: An escalating problem. BMJ 2002;324:1563-1566.
117. Enserink M. A mosquito goes global. Science 2008;320:864-866.
118. Kroeger A, Nathan MB. Dengue: Setting the global research agenda. Lancet 2006;368:2193-2195. (Pubitemid 44958999)
119. Senior K. Dengue fever: What hope for control? Lancet Infect Dis 2007;7:636.
120. Borgherini G, Poubeau P, Staikowsky F, Lory M, Le Moullec N, Becquart JP, Wengling C, Michault A, Paganin F. Outbreak of chikungunya on Reunion Island: Early clinical and laboratory features in 157 adult patients. Clin Infect Dis 2007;44:1401-1407.
121. Nicoletti L, Ciccozzi M, Marchi A, Fiorentini C, Martucci P, D'Ancona F, Ciofi degli Atti M, Pompa MG, Rezza G, Ciufolini MG. Chikungunya and dengue viruses in travelers. Emerg Infect Dis 2008;14:177-178.
122. Ratsitorahina M, Harisoa J, Ratovonjato J, Biacabe S, Reynes JM, Zeller H, Raoelina Y, Talarmin A, Richard V, Louis Soares J. Outbreak of dengue and Chikungunya fevers, Toamasina, Madagascar, 2006. Emerg Infect Dis 2008;14:1135-1137. (Pubitemid 351920450)
123. Bausch DG, Sprecher AG, Jeffs B, Boumandouki P. Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res 2008;78:150-161.
124. Bird BH, Githinji JW, Macharia JM, Kasiiti JL, Muriithi RM, Gacheru SG, Musaa JO, Towner JS, Reeder SA, Oliver JB, Stevens TL, Erickson BR, Morgan LT, Khristova ML, Hartman AL, Comer JA, Rollin PE, Ksiazek TG, Nichol ST. Multiple virus lineages sharing recent common ancestry were associated with a Large Rift Valley fever outbreak among livestock in Kenya during 2006-2007. J Virol 2008;82:11152-11166.
125. Madani TA. Alkhumra virus infection, a new viral hemorrhagic fever in Saudi Arabia. J Infect 2005;51:91-97.
126. Bray M. Highly pathogenic RNA viral infections: Challenges for antiviral research. Antiviral Res 2008;78:1-8.
127. Greenstone H, Spinelli B, Tseng C, Peacock S, Taylor K, Laughlin C. NIAID resources for developing new therapies for severe viral infections. Antiviral Res 2008;78:51-59. (Pubitemid 351381178)
128. De Clercq E. Strategies in the design of antiviral drugs. Nat Rev Drug Discov 2002;1:13-25.
129. De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2004;2:704-720.
130. Leyssen P, De Clercq E, Neyts J. Perspectives for the treatment of infections with Flaviviridae. Clin Microbiol Rev 2000;13:67-82.
131. Leyssen P, De Clercq E, Neyts J. Molecular strategies to inhibit the replicatin of RNA viruses. Antiviral Res 2008;78:9-25.
132. Norrby E. Nobel Prizes and the emerging virus concept. Arch Virol 2008;153:1109-1123.
133. Monath TP. Treatment of yellow fever. Antiviral Res 2008;78:116-124.
134. Perera R, Khaliq M, Kuhn RJ. Closing the door on flaviviruses: Entry as a target for antiviral drug design. Antiviral Res 2008;80:11-22.
135. Sampath A, Padmanabhan R. Molecular targets for flavivirus drug discovery. Antiviral Res 2009;81:6-15.
136. Malet H, Massé N, Selisko B, Romette JL, Alvarez K, Guillemot JC, Tolou H, Yap TL, Vasudevan S, Lescar J, Canard B. The flavivirus polymerase as a target for drug discovery. Antiviral Res 2008;80:23-35.
137. Charlier N, Leyssen P, De Clercq E, Neyts J. Rodent models for the study of therapy against flavivirus infections. Antiviral Res 2004;63:67-77. (Pubitemid 39061771)
138. Leyssen P, Van Lommel A, Drosten C, Schmitz H, De Clercq E, Neyts J. A novel model for the study of the therapy of flavivirus infections using the Modoc virus. Virology 2001;279:27-37. (Pubitemid 34160996)
139. Charlier N, Leyssen P, Paeshuyse J, Drosten C, Schmitz H, Van Lommel A, De Clercq E, Neyts J. Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis. J Gen Virol 2002;83:1887-1896.
140. Khan SH, Goba A, Chu M, Roth C, Healing T, Marx A, Fair J, Guttieri MC, Ferro P, Imes T, Monagin C, Garry RF, Bausch DG. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res 2008;78:103-115.
141. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986;314:20-26.
142. Gowen BB, Smee DF, Wong MH, Pace AM, Jung KH, Bailey KW, Blatt LM, Sidwell RW. Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters. Antivir Chem Chemother 2006;17:175-183.
143. Carrion Jr R, Brasky K, Mansfield K, Johnson C, Gonzales M, Ticer A, Lukashevich I, Tardif S, Patterson J. Lassa virus infection in experimentally infected marmosets: Liver pathology and immunophenotypic alterations in target tissues. J Virol 2007;81:6482-6490.
144. Sbrana E, Mateo RI, Xiao SY, Popov VL, Newman PC, Tesh RB. Clinical laboratory, virologic, and pathologic changes in hamsters experimentally infected with Pirital virus (Arenaviridae): A rodent model of Lassa fever. Am J Trop Med Hyg 2006;74:1096-1102. (Pubitemid 351627423)
145. Näslund J, Lagerqvist N, Lundkvist A, Evander M, Ahlm C, Bucht G. Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR. J Virol Methods 2008;151:277-282.
146. Bray M, Murphy FA. Filovirus research: Knowledge expands to meet a growing threat. J Infect Dis 2007;196:S438-S443. (Pubitemid 351417292)
147. Zampieri CA, Sullivan NJ, Nabel GJ. Immunopathology of highly virulent pathogens: Insights from Ebola virus. Nat Immunol 2007;8:1159-1164.
148. Rigau-Pérez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. Dengue and dengue haemorrphagic fever. Lancet 1998;352:971-977.
149. Halstead SB. Dengue. Lancet 2007;370:1644-1652.
150. Yap TL, Xu T, Chen Y-L, Malet H, Egloff M-P, Canard B, Vasudevan SG, Lescar J. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 185-angstrom resolution. J Virol 2007;81:4763-4765. (Pubitemid 46668672)
151. Benarroch D, Egloff M-P, Mulard L, Guerreiro C, Romette J-L, Canard B. A structural basis for the inhibition of the NS5 dengue virus mRNA 2′-O-methyltransferase domain by ribavirin 5′-triphosphate. J Biol Chem 2004;279:35638-35643. (Pubitemid 39100566)
152. Zhou Y, Ray D, Zhao Y, Dong H, Ren S, Li Z, Guo Y, Bernard KA, Shi P-Y, Li H. Structure and function of flavivirus NS5 methyltransferase. J Virol 2007;81:3891-3903. (Pubitemid 46586885)
153. Xu T, Sampath A, Chao A, Wen D, Nanao M, Chene P, Vasudevan SG, Lescar J. Structure of the dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 Å. J Virol 2005;79:10278-10288. (Pubitemid 41098569)
154. Melino S, Paci M. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach. FEBS J 2007;274:2986-3002.
155. Lescar J, Luo D, Xu T, Sampath A, Lim SP, Canard B, Vasudevan SG. Towards the design of antiviral inhibitors against flaviviruses: The case for the multifunctional NS3 protein from Dengue virus as a target. Antiviral Res 2008;80:94-101.
156. De Clercq E. John Montgomery's legacy: Carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity. Nucleosides Nucleotides Nucleic Acids 2005;24:1395-1415. (Pubitemid 41831807)
157. Koff WC, Elm Jr JL, Halstead SB. Inhibition of dengue virus replication by amantadine hydrochloride. Antimicrob Agents Chemother 1980;18:125-129. (Pubitemid 10039799)
158. Koff WC, Elm Jr JL, Halstead SB. Suppression of dengue virus replication in vitro by rimantadine hydrochloride. Am J Trop Med Hyg 1981;30:184-189.
159. Koff WC, Elm Jr JL, Halstead SB. Antiviral effects if ribavirin and 6-mercapto-9-tetrahydro-2-furylpurine against dengue viruses in vitro. Antiviral Res 1982;2:69-79. (Pubitemid 12011821)
160. Malinoski FJ, Hasty SE, Ussery MA, Dalrymple JM. Prophylactic ribavirin treatment of dengue virus type 1 infection in rhesus monkeys. Antiviral Res 1990;13:139-150.
161. Koff WC, Pratt RD, Elm Jr JL, Vekatseshan CN, Halstead SB. Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin. Antimicrob Agents Chemother 1983;24:134-136.
162. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 2000;74:4957-4966. (Pubitemid 30313834)
163. Ajariyakhajorn C, Mammen Jr MP, Endy TP, Gettayacamin M, Nisalak A, Nimmannitya S, Libraty DH. Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys. Antimicrob Agents Chemother 2005;49:4508-4514. (Pubitemid 41552579)
164. Yauch LE, Shresta S. Mouse models of dengue virus infection and disease. Antiviral Res 2008;80:87-93.
165. Schul W, Liu W, Xu H-Y, Flamand M, Vasudevan SG. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007;195:665-674. (Pubitemid 46273039)
166. Wu S-F, Lee C-J, Liao C-L, Dwek RA, Zitzmann N, Lin Y-L. Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol 2002;76:3596-3604. (Pubitemid 34250524)
167. Whitby K, Pierson TC, Geiss B, Lane K, Engle M, Zhou Y, Doms RW, Diamond MS. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol 2005;79:8698-8706. (Pubitemid 40934780)
168. Gu B, Mason P, Wang L, Norton P, Bourne N, Moriarty R, Mehta A, Despande M, Shah R, Block T. Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir Chem Chemother 2007;18:49-59. (Pubitemid 46426937)
169. Puig-Basagoiti F, Tilgner M, Forshey BM, Philpott SM, Espina NG, Wentworth DE, Goebel SJ, Masters PS, Falgout B, Ren P, Ferguson DM, Shi PY. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob Agents Chemother 2006;50:1320-1329.
170. Birk AV, Dubovi EJ, Zhang X, Szeto HH. Antiviral activity of geneticin against bovine viral diarrhoea virus. Antivir Chem Chemother 2008;19:33-40.
171. Zhang XG, Mason PW, Dubovi EJ, Xu X, Bourne N, Renshaw RW, Block TM, Birk AV. Antiviral activity of geneticin against dengue virus. Antiviral Res 2009;83:21-27.
172. Vela EM, Bowick GC, Herzog NK, Aronson JF. Genistein treatment of cells inhibits arenavirus infection. Antiviral Res 2008;77:153-156.
173. Rees CR, Costin JM, Fink RC, McMichael M, Fontaine KA, Isern S, Michael SF. In vitro inhibition of dengue virus entry by p-sulfoxy-cinnamic acid and structurally related combinatorial chemistries. Antiviral Res 2008;80:135-142.
174. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 1997;3:866-871. (Pubitemid 27353446)
175. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 2002;292:162-168.
176. Ono L, Wollinger W, Rocco IM, Coimbra TL, Gorin PA, Sierakowski MR. In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (BeH111 strain) and dengue 1 virus (Hawaii strain). Antiviral Res 2003;60:201-208.
177. Talarico LB, Damonte EB. Interference in dengue virus adsorption and uncoating by carrageenans. Virology 2007;363:473-485.
178. Talarico LB, Pujol CA, Zibetti RGM, FarÍa PCS, Noseda MD, Duarte MER, Damonte EB. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res 2005;66:103-110.
179. Yu G, Gunay NS, Linhardt RJ, Toida T, Fareed J, Hoppensteadt DA, Shadid H, Ferro V, Li C, Fewings K, Palermo MC, Podger D. Preparation and anticoagulant activity of the phosphosulfomannan PI-88. Eur J Med Chem 2002;37:783-791. (Pubitemid 35350842)
180. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999;59:3433-3441. (Pubitemid 29334505)
181. Lee E, Pavy M, Young N, Freeman C, Lobigs M. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitis flaviviruses. Antiviral Res 2006;69:31-38. (Pubitemid 41790479)
182. Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E. Antiviral peptides targeting the West Nile virus envelope protein. J Virol 2007;81:2047-2055. (Pubitemid 46214476)
183. Kinney RM, Huang CY-H, Rose BC, Kroeker AD, Dreher TW, Iversen PL, Stein DA. Inhibition of dengue virus serotypes 1 to 4 in Vero cell cultures with morpholino oligomers. J Virol 2005;79:5116-5128.
184. Stein DA, Huang CY, Silengo S, Amantana A, Crumley S, Blouch RE, Iversen PL, Kinney RM. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J Antimicrob Chemother 2008;62:555-565.
185. De Clercq E, Holý A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nat Rev Drug Discov 2005;4:928-940. (Pubitemid 41637695)
186. De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: Historical perspective. Antiviral Res 2007;75:1-13. (Pubitemid 46610520)
187. De Clercq E, Andrei G, Balzarini J, Leyssen P, Naesens L, Neyts J, Pannecouque C, Snoeck R, Ying C, Hocková D, Holý A. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids 2005;24:331-341. (Pubitemid 41440607)
188. Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holý A, De Clercq E, Niesters HG, Fries E, Maas C, Mulder PG, van der Zeijst BA, Osterhaus AD. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 2006;439:745-748. (Pubitemid 43237623)
189. De Clercq E. Therapeutic potential of HPMPC as an antiviral drug. Rev Med Virol 1993;3:85-96.
190. Gibson JS, Slater JD, Field HJ. The activity of (S)-1-[(3-hydroxy-2- phosphonyl methoxy) propyl] cytosine (HPMPC) against equine herpesvirus-1 (EHV-1) in cell cultures, mice and horses. Antiviral Res 1992;19:219-232.
191. Gilliam SE, Field HJ. The effect of (S)-1-(3-hydroxy-2-phosphonyl- methoxypropyl)cytosine (HPMPC) on bovine herpesvirus-1 (BHV-1) infection and reactivation in cattle. Antiviral Res 1993;20:21-32.
192. Garré B, van der Meulen K, Nugent J, Neyts J, Croubels S, De Backer P, Nauwynck H. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Vet Microbiol 2007;122:43-51.
193. van der Meulen K, Garré B, Croubels S, Nauwynck H. In vitro comparison of antiviral drugs against feline herpesvirus 1. BMC Vet Res 2006;2:13.
194. Hussein ITM, Field HJ. Development of a quantitative real-time TaqMan PCR assay for testing the susceptibility of feline herpesvirus-1 to antiviral compounds. J Virol Methods 2008;152:85-90.
195. Fontenelle JP, Powell CC, Veir JK, Radecki SV, Lappin MR. Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats. Am J Vet Res 2008;69:289-293.
196. Tempesta M, Camero M, Bellacicco AL, Thiry J, Crescenzo G, Neyts J, Thiry E, Buonavoglia C. Cidofovir is effective against caprine herpesvirus 1 infection in goats. Antiviral Res 2007;74:138-141. (Pubitemid 46436168)
197. Tempesta M, Camero M, Bellacicco AL, Tarsitano E, Crescenzo G, Thiry J, Martella V, Decaro N, Elia G, Neyts J, Thiry E, Buonavoglia C. Potent inhibition of genital herpesvirus infection in goats by cidofovir. Antivir Ther 2007;12:977-979. (Pubitemid 47492568)
198. Tempesta M, Crescenzo G, CameroM, Bellacicco AL, Tarsitano E, Decaro N, Neyts J, Martella V, Buonavoglia C. Assessing the efficacy of cidofovir against herpesvirus-induced genital lesions in goats using different therapeutic regimens. Antimicrob Agents Chemother 2008;52:4064-4068.
199. Osterhaus AD, Groen J, De Clercq E. Selective inhibitory effects of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine and 1-(2′-deoxy- 2′-fluoro-beta-D-arabinofuranosyl)-5-iodouracil on seal herpesvirus (phocid herpesvirus 1) infection in vitro. Antiviral Res 1987;7:221-226. (Pubitemid 17116287)
200. De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986;323:464-467. (Pubitemid 16026278)
201. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987;8:261-272. (Pubitemid 18073222)
202. De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev 2001;14:382-397. (Pubitemid 32294676)
203. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002;55:1-13.
204. Neyts J, Leyssen P, Verbeken E, De Clercq E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob Agents Chemother 2004;48:2267-2273. (Pubitemid 38691628)
205. Duraffour S, Snoeck R, Krecmerová M, van Den Oord J, De Vos R, Holý A, Crance JM, Garin D, De Clercq E, Andrei G. Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models. Antimicrob Agents Chemother 2007;51:4410-4419. (Pubitemid 350209897)
206. Adams MM, Rice AD, Moyer RW. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J Virol 2007;81:11084-11095. (Pubitemid 47536081)
207. Parker S, Schriewer J, Oberle C, Robertson A, Lanier R, Painter G, Buller RM. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001. Antivir Ther 2008;13:863-873.
208. Schultz DA, Sagartz JE, Huso DL, Buller RML. Experimental infection of an African dormouse (Graphiurus kelleni) with monkeypox virus. Virology 2009;383:86-92.
209. Smee DF, Gowen BB, Wandersee MK, Wong MH, Skirpstunas RT, Baldwin TJ, Hoopes JD, Sidwell RW. Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment. Int J Antimicrob Agents 2008;31:352-359.
210. Vorou RM, Papavassiliou VG, Pierroutsakos IN. Cowpox virus infection: An emerging health threat. Curr Opin Infect Dis 2008;21:153-156.
211. Jesus DM, Moussatché N, Damaso CR. In vitro activity of cidofovir against the emerging Cantagalo virus and the smallpox vaccine strain IOC. Int J Antimicrob Agents 2009;33:75-79.
212. Damaso CR, Esposito JJ, Condit RC, Moussatché N. An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine. Virology 2000;277:439-449.
213. Nettleton PF, Gilray JA, Reid HW, Mercer AA. Parapoxviruses are strongly inhibited in vitro by cidofovir. Antiviral Res 2000;48:205-208.
214. Dal Pozzo F, Andrei G, Lebeau I, Beadle JR, Hostetler KY, De Clercq E, Snoeck R. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral Res 2007;75:52-57.
215. Dal Pozzo F, Andrei G, Holý A, Van Den Oord J, Scagliarini A, De Clercq E, Snoeck R. Activities of acyclic nucleoside phosphonates against Orf virus in human and ovine cell monolayers and organotypic ovine raft cultures. Antimicrob Agents Chemother 2005;49:4843-4852. (Pubitemid 41778893)
216. Nollens HH, Gulland FM, Jacobson ER, Hernandez JA, Klein PA, Walsh MT, Condit RC. In vitro susceptibility of sea lion poxvirus to cidofovir. Antiviral Res 2008;80:77-80.
217. Geerinck K, Lukito G, Snoeck R, De Vos R, De Clercq E, Vanrenterghem Y, Degreef H, Maes B. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol 2001;64:543-549. (Pubitemid 32613744)
218. Scagliarini A, McInnes CJ, Gallina L, Dal Pozzo F, Scagliarini L, Snoeck R, Prosperi S, Sales J, Gilray JA, Nettleton PF. Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs. Antiviral Res 2007;73:169-174. (Pubitemid 46298525)
219. Naesens L, Balzarini J, Rosenberg I, Holý A, De Clercq E. 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): A novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. Eur J Clin Microbiol Infect Dis 1989;8:1043-1047. (Pubitemid 20018476)
220. Naesens L, Balzarini J, De Clercq E. Single-dose administration of 9-(2-phosphonylmethoxyethyl) adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2, 6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res 1991;16:53-64.
221. Naesens L, Neyts J, Balzarini J, Holý A, Rosenberg I, De Clercq E. Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice. J Med Virol 1993;39:167-172. (Pubitemid 23062367)
222. Egberink H, Borst M, Niphuis H, Balzarini J, Neu H, Schellekens H, De Clercq E, Horzinek M, Koolen M. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl) adenine. Proc Natl Acad Sci USA 1990;87:3087-3091. (Pubitemid 20144959)
223. Hartmann K, Kuffer M, Balzarini J, Naesens L, Goldberg M, Erfle V, Goebel FD, De Clercq E, Jindrich J, Holy A, Bischofberger N, Kraft W. Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl) adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl) adenine (PMEA) against feline immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:120-128. (Pubitemid 128702524)
224. Vahlenkamp TW, De Ronde A, Balzarini J, Naesens L, De Clercq E, van Eijk MJ, Horzinek MC, Egberink HF. (R)-9-(2-Phosphonylmethoxypropyl)-2,6- diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrob Agents Chemother 1995;39:746-749.
225. Balzarini J, Holý A, Jindrich J, Naesens L, Snoeck R, Schols D, De Clercq E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)- 2,6-diaminopurine. Antimicrob Agents Chemother 1993;37:332-338.
226. Holý A, Votruba I, Masojídková M, Andrei G, Snoeck R, Naesens L, De Clercq E, Balzarini J. 6-[2-(Phosphonomethoxy)alkoxy] pyrimidines with antiviral activity. J Med Chem 2002;45:1918-1929.
227. Hocková D, Holý A, Masojídková M, Andrei G, Snoeck R, De Clercq E, Balzarini J. 5-Substituted-2,4-diamino-6-[2- (phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity. J Med Chem 2003;46:5064-5073. (Pubitemid 37352043)
228. Krecmerová M, Holý A, Pískala A, Masojídková M, Andrei G, Naesens L, Neyts J, Balzarini J, De Clercq E, Snoeck R. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. J Med Chem 2007;50:1069-1077. (Pubitemid 46394009)
229. Naesens L, Andrei G, Votruba I, Krecmerová M, Holý A, Neyts J, De Clercq E, Snoeck R. Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)-propyl]-5-azacytosine. Biochem Pharmacol 2008;76:997-1005.
230. Tulman ER, Afonso CL, Lu Z, Zsak L, Sur JH, Sandybaev NT, Kerembekova UZ, Zaitsev VL, Kutish GF, Rock DL. The genomes of sheeppox and goatpox viruses. J Virol 2002;76:6054-6061.
231. Waltzek TB, Kelley GO, Stone DM, Way K, Hanson L, Fukuda H, Hirono I, Aoki T, Davison AJ, Hedrick RP. Koi herpesvirus represents a third cyprinid herpesvirus (CyHV-3) in the family Herpesviridae. J Gen Virol 2005;85:1659-1667. (Pubitemid 40766877)
232. Ilouze M, Dishon A, Kahan T, Kotler M. Cyprinid herpes virus-3 (CyHV-3) bears genes of genetically distant large DNA viruses. FEBS Lett 2006;580:4473-4478. (Pubitemid 44118268)
233. Davidovich M, Dishon A, Ilouze M, Kotler M. Susceptibility of cyprinid cultured cells to cyprinid herpesvirus 3. Arch Virol 2007;152:1541-1546. (Pubitemid 47124958)
234. Dishon A, Davidovich M, Ilouze M, Kotler M. Persistence of cyprinid herpesvirus 3 in infected cultured carp cells. J Virol 2007;81:4828-4836. (Pubitemid 46668679)
235. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003;16:569-596. (Pubitemid 37296550)
236. Calista D. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. J Eur Acad Dermatol Venereol 2000;14:484-488. (Pubitemid 32899272)
237. Davis MD, Gostout BS, McGovern RM, Persing DH, Schut RL, Pittelkow MR. Large plantar wart caused by human papillomavirus-66 and resolution by topical cidofovir therapy. J Am Acad Dermatol 2000;43:340-343.
238. Hengge UR, Tietze G. Successful treatment of recalcitrant condyloma with topical cidofovir. Sex Transm Infect 2000;76:143. (Pubitemid 30262259)
239. De Socio GV, Simonetti S, Rosignoli D, Minga P, Tomassini GM, Baldelli F. Topical cidofovir for severe warts in a patient affected by AIDS and Hodgkin's lymphoma. Int J STD AIDS 2008;19:715-716.
240. Coremans G, Margaritis V, Snoeck R, Wyndaele J, De Clercq E, Geboes K. Topical cidofovir (HPMPC) is an effective adjuvant to surgical treatment of anogenital condylomata acuminata. Dis Colon Rectum 2003;46:1103-1108.
241. Bonatti H, Aigner F, De Clercq E, Boesmueller C, Widschwendner A, Larcher C, Margreiter R, Schneeberger S. Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. Transpl Int 2007;20:238-246.
242. Gröne D, Treudler R, de Villiers EM, Husak R, Orfanos CE, Zouboulis ChC. Intravenous cidofovir treatment for recalcitrant warts in the setting of a patient with myelodysplastic syndrome. J Eur Acad Dermatol Venereol 2006;20:202-205.
243. Van Cutsem E, Snoeck R, Van Ranst M, Fiten P, Opdenakker G, Geboes K, Janssens J, Rutgeerts P, Vantrappen G, De Clercq E. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine. J Med Virol 1995;45:230-235.
244. Snoeck R, Wellens W, Desloovere C, Van Ranst M, Naesens L, De Clercq E, Feenstra L. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine]. J Med Virol 1998;54:219-225.
245. Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol 2000;60:205-209.
246. Snoeck R, Van Laethem Y, De Clercq E, De Maubeuge J, Clumeck N. Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome. Arch Intern Med 2001;161:2382-2384. (Pubitemid 32980138)
247. Van Valckenborgh I, Wellens W, De Boeck K, Snoeck R, De Clercq E, Feenstra L. Systemic cidofovir in papillomatosis. Clin Infect Dis 2001;32:E62-E64.
248. Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, Van Ranst M, Noël JC, Wulfsohn MS, Rooney JF, Jaffe HS, De Clercq E. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 2001;33:597-602. (Pubitemid 32762931)
249. Stragier I, Snoeck R, De Clercq E, Van Den Oord JJ, Van Ranst M, De Greef H. Local treatment of HPV-induced skin lesions by cidofovir. J Med Virol 2002;67:241-245. (Pubitemid 34493438)
250. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol Res 1998;10:523-531. (Pubitemid 128736341)
251. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice. Oncol Res 1998;10:533-539. (Pubitemid 128736342)
252. Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res 2001;12:1397-1408.
253. Johnson JA, Gangemi JD. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine. Antimicrob Agents Chemother 1999;43:1198-1205. (Pubitemid 29214747)
254. Christensen ND, Pickel MD, Budgeon LR, Kreider JW. In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. Antiviral Res 2000;48:131-142.
255. Abdulkarim B, Sabri S, Deutsch E, Chagraoui H, Maggiorella L, Thierry J, Eschwege F, Vainchenker W, Chouaïb S, Bourhis J. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002;21:2334-2346. (Pubitemid 34407293)
256. Donne AJ, Hampson L, He XT, Rothera MP, Homer JJ, Hampson IN. Effects of cidofovir on a novel cell-based test system for recurrent respiratory papillomatosis. Head Neck 2007;29:741-750. (Pubitemid 47265529)
257. De Clercq E. Acyclic nucleoside phosphonates: Past, present and future bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: The phosphonate bridge. Biochem Pharmacol 2007;73:911-922.
258. Wiatrak BJ. Overview of recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg 2008;11:433-441.
259. Tasca RA, Clarke RW. Recurrent respiratory papillomatosis. Arch Dis Child 2006;91:689-691.
260. Dancey DR, Chamberlain DW, Krajden M, Palefsky J, Alberti PW, Downey GP. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: Case report and review of the literature. Chest 2000;118:1210-1214.
261. Armbruster C, Kreuzer A, Vorbach H, Huber M, Armbruster C. Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b. Eur Respir J 2001;17:830-831. (Pubitemid 32492573)
262. Mandell DL, Arjmand EM, Kay DJ, Casselbrant ML, Rosen CA. Intralesional cidofovir for pediatric recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2004;130:1319-1323. (Pubitemid 39532268)
263. Peyton Shirley W, Wiatrak B. Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children? Int J Pediatr Otorhinolaryngol 2004;68:413-418.
264. Shehab N, Sweet BV, Hogikyan ND. Cidofovir for the treatment of recurrent respiratory papillomatosis: A review of the literature. Pharmacotherapy 2005;25:977-989. (Pubitemid 40917930)
265. Silverman DA, Pitman MJ. Current diagnostic and management trends for recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg 2004;12:532-537. (Pubitemid 39565210)
266. Neumann K, Pudszuhn A, Welzel C, Bartel-Friedrich S, Passmann M. Intralesional cidofovir injections for recurrent laryngeal papillomatosis: First results. Laryngo-Rhino-Otol 2003;82:700-706. (Pubitemid 37345449)
267. Naiman AN, Ayari S, Nicollas R, Landry G, Colombeau B, Froehlich P. Intermediate-term and long-term results after treatment by cidofovir and excision in juvenile laryngeal papillomatosis. Ann Otol Rhinol Laryngol 2006;115:667-672. (Pubitemid 44449642)
268. Naiman AN, Abedipour D, Ayari S, Fresnel E, Coulombeau B, Bour JB, Froehlich P. Natural history of adult-onset laryngeal papillomatosis following multiple cidofovir injections. Ann Otol Rhinol Laryngol 2006;115:175-181.
269. Pudszuhn A, Welzel C, Bloching M, Neumann K. Intralesional cidofovir application in recurrent laryngeal papillomatosis. Eur Arch Otorhinolaryngol 2007;264:63-70. (Pubitemid 44900302)
270. Donne AJ, Rothera MP, Homer JJ. Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2008;72:939-944.
271. Sirianni N, Wang J, Ferris RL. Antiviral activity of cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol 2005;41:423-428. (Pubitemid 40387872)
272. Capaccio P, Ottaviani F, Cuccarini V, Corbellino M, Parravicini C, Menzo S, Schindler A, Pignataro L. Surgery and topic cidofovir for nasal squamous papillomatosis in HIV+ patient. Eur Arch Otorhinolaryngol 2009;266:937-939.
273. Kimberlin DW. Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res 2004;63:141-151. (Pubitemid 39286751)
274. Inglis Jr AF. Cidofovir and the black box warning. Ann Otol Rhinol Laryngol 2005;114:834-835.
275. Münch J, Rücker E, Ständker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, Giménez-Gallego G, Sánchez PC, Fowler DM, Koulov A, Kelly JW, Mothes W, Grivel JC, Margolis L, Keppler OT, Forssmann WG, Kirchhoff F. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007;131:1059-1071. (Pubitemid 350235017)
276. Tsai C-C, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, Benveniste RE, Black R. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995;270:1197-1198.
277. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, Lifson JD, Morton WR. Effectiveness of postinoculation (R)-9-(2- phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265-4273.
278. Otten RA, Smith DK, Adams DR, Pullium JK, Jackson E, Kim CN, Jaffe H, Janssen R, Butera S, Folks TM. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000;74:9771-9775.
279. Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, Monsour M, Adams DR, Bashirian S, Johnson J, Soriano V, Rendon A, Hudgens MG, Butera S, Janssen R, Paxton L, Greenberg AE, Folks TM. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006;194:904-911. (Pubitemid 44454075)
280. Van Rompay KK, McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N, Marthas ML. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis 2001;184:429-438. (Pubitemid 32718506)
281. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, Marthas ML, Reiser H, Bischofberger N. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: Summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008;52:3144-3160.
282. Mayer KH, Masiankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Masse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006;20:543-551. (Pubitemid 43731598)
283. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 2008;5:e157.
284. Dobard C, Parikh U, Sharma S, Cong M-E, Smith J, Garcia-Lerma G, Novembre F, Otten R, Folks T, Heneine W. Complete protection against repeated vaginal simian HIV exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. 16th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2009, Montréal, Canada. Oral Abstracts, No. 46.
285. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008;5:e16.
286. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, Luo
287. Garcia-Lerma G, Cong M-E, Mitchell J, Youngpairoj A, Martin A, Hanson D, Otten R, Paxton L, Folks T, Heneine W. Prevention of rectal simian HIV transmission in macaques by intermittent pre-exposure prophylaxis with oral Truvada. 16th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2009, Montréal, Canada. Oral Abstracts, No. 47.
288. Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: What if it works? Lancet 2007;370:89-93.
289. + cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques. AIDS Res Hum Retrovir 2008;24:543-546.
290. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, Grant R, Clarke EE, Doh AS, Ridzon R, Jaffe HS, Cates W. Tenofovir disoproxil fumarate for prevention of HIV infection in women: A phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007;2:e27. (Pubitemid 46851988)
291. Olmscheid B, Zhang S. Use of tenofovir disoproxil fumarate (TDF) in pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR). 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC, USA, 25-28 October 2008. Poster H-456. 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC, USA, 25-28 October 2008. Poster 976.
292. Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann Pharmacother 2008;42:1581-1585.